Replies to post #18270 on Don't Bite The Hand That Feeds You

[sonny-888]

in VICL pre market 4.75
Vical Leaping Higher in Early Pre-Bell Trade on Preclinical Results with Vaxfectin Cancer Vaccine 09/24 07:09 AM

07:09 AM Eastern Daylight Time, 09/24/2009 (MidnightTrader) -- Vical (VICL:$4.22,00$-0.24,00-5.38%) announced the presentation of encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company's Vaxfectin adjuvant.

Sean M. Sullivan, Ph.D., Vical's (VICL:$4.22,00$-0.24,00-5.38%) Executive Director of Pharmaceutical Sciences, is presenting data at the IIRUSA Vaccines Development Forum demonstrating the adjuvant's ability to enhance immune responses of cancer antigen-based vaccines in addition to a broad variety of DNA- and protein-based vaccines against infectious diseases.

The company noted that the latest data showed that mice vaccinated with a Vaxfectin-formulated TRP-2 melanoma tumor antigen peptide achieved significant improvements in cellular immune responses, reduced numbers of tumors, and a survival advantage compared with mice receiving control or no treatment.

[Gator-Trader]

That would be GREAT. I really like there charts and they have a way to list all the stocks we are watching so we can all see the notes and trends you draw on the charts. It would help me see what you see.